Aptar Empowers Indian Pharma with Inhalers, Nasal Sprays for Global Markets

Aptar is assisting Indian pharmaceutical firms in the launch of inhalers and nasal sprays for both local and export markets. Aptar is the top global supplier of inhalation devices, essential for administering medications used to manage respiratory conditions like asthma and COPD.

The company revealed the inauguration of its new pharmaceutical facility in Taloja, close to Mumbai. The new facility will enhance the company’s current presence in the area while introducing more local manufacturing of various technologies, including Aptar’s pressurized metered dose inhaler (pMDI) valve, along with breath-actuated devices and single-dose nasal sprays.

The new Taloja facility will allow Aptar to address the increasing demands of the area by providing an extra 4400 square metres of production space and will be built next to the current Aptar Mumbai plant that launched in 2023.

“This additional plant in Taloja will further strengthen our ability to efficiently deliver high-quality, innovative products and reinforces our commitment to investing in the pharma end markets," said said Sanjay Kapote, President of Aptar Pharma India and Southeast Asia, commented,

"Additionally, we are keen on exploring acquisitions in the pharma space. We see significant growth potential within the pharmaceutical industry in India and the potential to expand our position in the market,” Kapote added.

Aptar seeks potential acquisitions and collaborations with IP-oriented, pharmaceutical packaging firms to further expand their drug dosing, dispensing, and protection services.